Abstract 1242: PD-L1 and PD-L2 mRNA are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer
Aileen I. Fernandez(Yale University), David L. Rimm(Yale University), Thazin Nwe Aung(Yale University), Jodi Weidler, Michael Bates, Vesal Yaghoobi(Yale University), Sandra Martínez-Morilla(Yale University), Leena McCann, Myrto Moutafi(University General Hospital Attikon), Saba Shafi(Ministry of Education of the People's Republic of China), Ioannis Vathiotis(Yale University), Yalai Bai(Yale University), Niki Gavrielatou(National and Kapodistrian University of Athens)
Cited by 0
Related Papers
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
|JAMA Oncology|2015|834
Programmed death ligand-1 expression in non-small cell lung cancer
|Laboratory Investigation|2013|753